Cargando…
Pharmacokinetic equivalence of CT‐P17 to high‐concentration (100 mg/ml) reference adalimumab: A randomized phase I study in healthy subjects
This study aimed to demonstrate pharmacokinetic (PK) equivalence of a single dose of the proposed adalimumab biosimilar CT‐P17 to United States‐licensed adalimumab (US‐adalimumab) and European Union‐approved adalimumab (EU‐adalimumab). This double‐blind, parallel‐group, phase I trial (clinicaltrials...
Autores principales: | Yu, Kyung‐Sang, Jang, In‐Jin, Lim, Hyeong‐Seok, Hong, Jang Hee, Kim, Min‐Gul, Park, Min Kyu, Cho, Doo‐Yeoun, Park, Min Soo, Chung, Jae Yong, Ghim, Jong‐Lyul, Lee, SeungHwan, Yoon, Seok Kyu, Kwon, In Sun, Lee, Sang Joon, Kim, Sung Hyun, Bae, Yun Ju, Cha, Jung Bin, Furst, Daniel E., Keystone, Edward, Kay, Jonathan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8301575/ https://www.ncbi.nlm.nih.gov/pubmed/33503313 http://dx.doi.org/10.1111/cts.12967 |
Ejemplares similares
-
Randomised, phase I pharmacokinetic study of adalimumab biosimilar CT‐P17 (40 mg/0.4 mL) by autoinjector and prefilled syringe in healthy subjects
por: Davidson, Antonia, et al.
Publicado: (2021) -
Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomized, double-blind study in rheumatoid arthritis
por: Furst, Daniel E, et al.
Publicado: (2021) -
Pharmacokinetics of fixed-dose combination of rosuvastatin 20 mg and ezetimibe 10 mg compared to concurrent administration of individual tablets in healthy Korean subjects
por: Hwang, Inyoung, et al.
Publicado: (2018) -
Frequency of peripheral diseases in Korean patients with ankylosing spondylitis and the effectiveness of adalimumab
por: Lee, Sang‐Hoon, et al.
Publicado: (2020) -
Carcinoembryonic Antigen Level Can be Overestimated in Metabolic Syndrome
por: Kim, Kyu-Nam, et al.
Publicado: (2011)